Skip to main content
. 2022 Feb 24;9:814756. doi: 10.3389/fcvm.2022.814756

Table 1.

Clinical statistics of the study population.

Dippers, Non-dippers, P
n = 111 n = 179
Age (years) 49.0 ± 12.3 52.5 ± 12.7* 0.021
Sex (n, %) males 56 (50.5%) 106 (59.2%) 0.147
Smoker (%) 28 (25.2%) 63 (35.2%) 0.091
DM (%) 30 (27.0%) 58 (32.4%) 0.360
HT duration(years) 5.0 (1.6, 10.0) 5.0 (2.0, 10.0) 0.380
eGFR (ml/min/1.73 m2) 116.3 ± 27.3 107.4 ± 23.7 0.004
BMI (kg/m2) 27.0 ± 3.7 27.1 ± 3.6 0.881
FPG (mmol/L) 5.4 (4.7, 6.3) 5.2 (4.6, 6.0) 0.326
HbA1c (%) 5.9 (5.5, 6.4) 5.9 (5.6, 6.4) 0.475
TC (mmol/L) 4.6 ± 0.9 4.8 ± 1.1 0.268
TG (mmol/L) 1.5 (1.1, 2.2) 1.5 (1.0, 2.1) 0.689
LDL-C (mmol/L) 2.7 ± 0.7 2.8 ± 0.8 0.491
HDL-C (mmol/L) 1.2 ± 0.3 1.2 ± 0.3 0.757
BNP (ng/L) 16.7 (9.3, 42.2) 24.4 (11.0, 46.9) 0.234
Hs-cTnI (μg/L) 0.01 (0.01, 0.01) 0.01 (0.00, 0.01) 0.841
Medications
CCB (%) 72 (64.9%) 115 (64.2%) 1.000
ACEI/ARB/ARNI (%) 47 (42.3%) 76 (42.5%) 1.000
β-blockers (%) 40 (36.0%) 45 (25.1%) 0.063
Diuretics (%) 11 (9.9%) 23 (12.8%) 0.574

DM, diabetes mellitus; HT duration, hypertension duration; BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BNP, B-type natriuretic peptide; Hs-cTnI, High-sensitive cardiac troponin I; CCB, calcium antagonists; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, Angiotensin receptor-neprilysin inhibitor.